September 17, 2020
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Revision to Earnings Forecasts for FY 2020and Mid-Range Plan (FY 2020 to FY 2022)
TOKYO, Japan, September 17, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,"SymBio") announced that the Company’s Board of Directors today approved the following revision tothe Earnings Forecast for fiscal year ending December 31, 2020 and the Mid-Range Plan for fiscal years
ending December 31, 2020, 2021 and 2022 that were previously announced on February 6, 2020. The
revisions reflect the Company’s current performance trends and outlook.
1. Revision to Earnings Forecast(1) Revision to the earnings forecast for FY 2020 (January 1, 2020 to December 31, 2020)
Earnings
OperatingOrdinaryNet
Net Sales(Loss)
Profit (Loss)
Profit (Loss)
Profit (Loss)
per Share
Yen millions

Yen millions

Yen millions

Yen millions

Yen

Previous Forecast (A)3,404(5,090)(5,134)(4,803)(146.98)

Revised Forecast (B)3,043(4,592)(4,656)(3,796)(116.16)

Change in Yen millions

(361)

498

478

1,007－(B-A)
Change Percentage (%)(10.6)

－－－－

2,837

(4,301)(4,376)(4,376)(189.03)[Reference] Prior YearResults (FY 2019)(2) Reasons for revision
Net Sales for the first half of FY 2020 were 1,361 million yen, a 32.1% decrease compared to the firsthalf of FY 2019. For the second half of FY 2020, the Company forecasts Net Sales of 1,682 million yen,mainly due to domestic market demand of TREAKISYM® trending higher and an increase in overseas
compared to H1. Also taking into consideration uncertainties in the business environment arising fromthe COVID-19 pandemic and other factors, Net Sales for the fiscal year ending December 2020 areanticipated to be 3,043 million yen, above prior year results but below the earning forecast for FY 20201

announced on February 6, 2020.
On the other hand, the Company is minimizing the impact from above-mentioned decrease in Net Sales
through company-wide cost saving initiatives to significantly reduce Selling, General andAdministrative Expenses, while prioritizing investments relating to the launch of SymBio’s own salesorganization in December 2020, achieving profitability in the FY 2021, and preparations for the global
phase 2 clinical study for brincidofovir planned to start in the first half of the FY 2021. The impact ofthe cost saving initiatives are reflected in the revised Operating Profit forecast.
In addition, the Company has reflected the arbitration award of USD 4,950,000 in the revised Net Profitforecast. Please see the press release “Final Arbitration Award in Dispute against The Medicines
Company” announced on September 1, 2020.
2. Revision to the Mid-Range Plan
(1) Previous vs Revised Plan
Previous Plan

Revised Planfor FY 2020

for FY 2020

Million of Yen

Million of Yen

3,404

3,043

Operating Profit (Loss)△5,090△4,592

Ordinary Profit (Loss)△5,134△4,656

Net Profit (Loss)△4,803△3,796Net Sales(2) Reasons for revision
Revisions have been made to reflect the revisions to the earnings forecast for FY 2020 discussed above.
The Company is currently assessing the potential impact on fiscal years 2021 and 2022 of the MidRange Plan. Any material impact will be disclosed by the Company in a timely manner.
*Earnings forecasts, financial projections, and other forecasts or forward looking statements containedin this disclosure have been prepared by the Company at its discretion and based on information
available to the Company as of the date of this disclosure. Actual results may vary materially from theinformation contained in this disclosure as a result of changes to business, economic, financial, or otherassumptions and conditions.
[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

2